Fusion Of Cells Patents (Class 435/449)
-
Publication number: 20120164733Abstract: An IVF system for successfully utilizing spermatozoa separated into X-chromosome bearing and into Y-chromosome bearing population for insemination. The IVF system includes fertilization medium that can shorten the time from insemination to cleavage and a portable incubator for the transportation of maturing oocytes and inseminated oocytes comprising a straw (19) and an incubation element (20) that can be sealed with a cap (22).Type: ApplicationFiled: February 24, 2012Publication date: June 28, 2012Inventors: George E. Seidel, Tae Kwang Suh, Kehuan Lu
-
Publication number: 20120151611Abstract: The present invention aims to provide a method for antibody preparation. The present invention is directed to a method for preparing an antibody-producing cell, which comprises the following steps: (1) transplanting metastatic cancer cells capable of expressing a target antigen into a non-human animal to ensure engraftment of the cancer cells in the animal; (2) immunizing the animal with the target antigen; and (3) collecting the antibody-producing cell from the immunized animal; as well as a method for preparing an antibody, which comprises collecting the antibody from the antibody-producing cell prepared by the above method.Type: ApplicationFiled: August 24, 2011Publication date: June 14, 2012Inventors: Hiroyuki Satofuka, Masahiro Uchino, Shingo Hanaoka
-
Publication number: 20120142106Abstract: This invention relates to the culture of dendritic cells from human embryonic stem (ES) cells. Human ES cells are first cultured into hematopoietic cells by co-culture with stromal cells. The cells now differentiated into the hematopoietic lineage are then cultured with GM-CSF to create a culture of myeloid precursor cells. Culture of the myeloid precursor cells with the cytokines GM-CSF and IL-4 causes functional dendritic cells to be generated. The dendritic cells have a unique phenotype, as indicated by their combination of cell surface markers.Type: ApplicationFiled: February 1, 2012Publication date: June 7, 2012Applicant: Wisconsin Alumni Research FoundationInventors: Igor I. Slukvin, James A. Thomson, Maksym A. Vodyanyk, Maryna E. Gumenyuk
-
Publication number: 20120129260Abstract: Methods are provided for producing a human embryo capable of developing to the blastocyst stage. The method includes transferring a human somatic cell genome into a mature human oocyte by nuclear transfer and activating the oocyte, without removing the oocyte genome. Pluripotent human embryonic stem cells, and methods of obtaining these, are also provided.Type: ApplicationFiled: November 22, 2011Publication date: May 24, 2012Applicant: THE NEW YORK STEM CELL FOUNDATIONInventors: Dietrich M. EGLI, Scott A. NOGGLE, Kevin C. EGGAN
-
Publication number: 20120088304Abstract: The present invention relates to cellular differentiation and, in particular to hybrid cells that exhibit phenotypic plasticity and methods for producing these cells. The invention also relates to methods for generating specific cells of a desired phenotype. The invention still further relates to methods of producing hybrid cells with a capacity to de-differentiate into an earlier progenitor state. The invention further contemplates the use of hybrid cells in a range of applications, for example tissue generation.Type: ApplicationFiled: June 10, 2010Publication date: April 12, 2012Applicant: Stephen Sanig Research Institute Ltd.Inventors: Galina Kaseko, Tohsak L. Mahaworasilpa
-
Publication number: 20120088272Abstract: The present invention relates to hybrid cells and methods for producing hybrid cells. In particular, the invention relates to hybrid cells generated from the hybridization of at least three cells where at least two cells are derived from different lineages. The invention further relates to the use of hybrid cells for the expression of proteins useful in a range of diagnostic, prophylactic, therapeutic and/or research applications.Type: ApplicationFiled: June 10, 2010Publication date: April 12, 2012Applicant: BTS Research International Pty LtdInventors: Galina Kaseko, Tohsak L. Mahaworasilpa
-
Patent number: 8119120Abstract: Methods disclosed include methods of treating T1DM, said method comprising delivering a therapeutic amount of ?-MSC to a subject in need thereof. Further disclosed are fusion cells comprising and MSC and a second cell wherein the nuclei of the MSC and the second cell are not fused in the fusion cell.Type: GrantFiled: September 19, 2007Date of Patent: February 21, 2012Assignee: Insugen, LLCInventor: Christof Westenfelder
-
Publication number: 20120036591Abstract: Methods are provided for producing a primate oocyte in vitro. The methods include removing nuclear DNA from a recipient primate oocyte from a first primate in a manner that does not lower levels of maturation promoting factor (MPF) to form an enucleated recipient primate oocyte. The recipient primate oocyte is enucleated using a non-UV-based spindle imaging system. Nuclear genetic material or DNA including chromosomes from a donor primate oocyte arrested at metaphase II from a second primate is isolated in the form of the karyoplast and introduced into the enucleated recipient primate oocyte. Introduction of the chromosomes is performed using a fusogenic agent or electroporation to produce a hybrid oocyte.Type: ApplicationFiled: April 22, 2010Publication date: February 9, 2012Inventor: Shoukhrat M. Mitalipov
-
Patent number: 8084578Abstract: Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper ?-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypo ?-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like.Type: GrantFiled: October 15, 2009Date of Patent: December 27, 2011Assignee: Fuso Pharmaceutical Industries, Ltd.Inventor: Nobutaka Wakamiya
-
Publication number: 20110305701Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.Type: ApplicationFiled: June 8, 2011Publication date: December 15, 2011Inventors: Neil R. Cashman, Joachim Bernhard Ostermann, Avijit Chakrabartty, Rishi Rakhit
-
Patent number: 8058505Abstract: A cytoplasmic male sterile cybrid plant of the genus Lactuca, a progeny thereof, or a part thereof having a gene derived from the mitochondria of a plant of the genus Helianthus in its cytoplasm and methods of producing first filial generation seeds using such a cybrid plant.Type: GrantFiled: October 20, 2006Date of Patent: November 15, 2011Assignee: Sakata Seed CorporationInventor: Shingo Horiuchi
-
Patent number: 8043838Abstract: An electroporation cuvette is constructed with electroporation electrodes arranged in non-parallel relation to form a gap whose width varies with the location within the cuvette, plus a pair of positioning electrodes that are arranged to cause electrophoretic migration of biological cells within the cuvette according to cell size. Once the cells, suspended in a solution of the impregnant, are distributed in the cuvette by the positioning electrodes, electric field pulses are generated by the non-parallel electroporation electrodes. Because of their distribution in the cuvette, the various cells will experience voltage differentials across their widths that approach uniformity regardless of cell diameter, since the larger cells will be positioned at locations where the gap between the electrodes is greater and the smaller cells at locations where the gap is relatively small while the voltage drop across the entire gap is uniform along the length of the cell.Type: GrantFiled: February 5, 2009Date of Patent: October 25, 2011Assignee: Bio-Rad Laboratories, Inc.Inventor: Charles W. Ragsdale
-
Publication number: 20110244450Abstract: Purified totipotent stem cells and pluripotent stems cells derived by somatic cell nuclear transfer are disclosed herein, as well as cell lines, multipotent cells and differentiated cells produced from these stem cells. The stem cells are produced from an enucleated host cell from a first donor and nuclear genetic material from a somatic cell of a second donor. Methods for making and using such compositions of such stem cells are also provided.Type: ApplicationFiled: May 31, 2011Publication date: October 6, 2011Inventors: Shoukhrat M. Mitalipov, Don P. Wolf, James Byrne
-
Publication number: 20110178182Abstract: A method of producing a nanostructure composition from a solid powder is disclosed. The method comprises: (a) heating the solid powder, thereby providing a heated solid powder; (b) immersing the heated solid powder in a liquid in the presence of a gas medium, the liquid being colder than the heated powder, and (c) irradiating the cold liquid, the heated solid powder and the gas medium by electromagnetic radiation selected such that nanostructures are formed from particles of the solid powder and a stable gas phase is formed from the gas medium.Type: ApplicationFiled: August 20, 2008Publication date: July 21, 2011Inventor: Eran Gabbai
-
Publication number: 20110172288Abstract: The subject matter relates to newly discovered nucleic acid molecules and proteins associated with thymic lymphoma and hamartomatous tumors. Compositions and methods for detecting, characterizing, preventing, and treating human thymic lymphoma and hamartomatous tumors are provided.Type: ApplicationFiled: August 26, 2010Publication date: July 14, 2011Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Ronald A. DePinho, Ji-Hye Paik, Ramya Kollipara
-
Patent number: 7972855Abstract: There are provided microorganisms, for example, Mortierella alpina, having a property of producing a lipid containing unsaturated fatty acids as constituent fatty acids and extracellularly secreting the produced lipid encapsulated in lipid vesicles, methods of screening said microorganisms, as well as methods of efficiently producing a fatty acid-containing lipid using said microorganisms. Furthermore, there are provided lipid vesicles encapsulating a lipid containing unsaturated fatty acids, and foods, cosmetics, and animal feeds comprising said lipid vesicles added thereto. Artificially treated microorganisms or microorganisms collected from nature are grown on a solid medium, and microbial strains that form lipid vesicles at the periphery of the colonies and/or microbial strains that, when cultured in a transparent liquid medium, make the culture liquid cloudy are selected.Type: GrantFiled: December 1, 2006Date of Patent: July 5, 2011Assignee: Suntory Holdings LimitedInventors: Kengo Akimoto, Hiroshi Kawashima, Sakayu Shimizu
-
Publication number: 20110158988Abstract: The present invention relates to an affinity ligand capable of selective interaction with a subset consisting of 37 consecutive amino acid residues or less from extracellular domains 2 and 3 of HER2, wherein the subset comprises the amino acid sequence LQVF and/or ESFDGD1 and to polypeptides consisting of such subsets.Type: ApplicationFiled: December 12, 2008Publication date: June 30, 2011Applicant: ATLAS THERAPEUTICS ABInventors: Mathias Uhlen, Johan Rockberg
-
Patent number: 7968093Abstract: This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodies, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.Type: GrantFiled: December 17, 2009Date of Patent: June 28, 2011Assignee: ImClone LLCInventor: Dale L Ludwig
-
Publication number: 20110110903Abstract: It is intended to provide a regeneration promoter for regenerating a tissue with the use of somatic stem cells. It is also intended to provide a cell fusion promoter safely usable in vivo. Namely, it is intended to provide a cell fusion promoter comprising ATP or its metabolite. A cell fusion promoter comprising ATP or its metabolite and a method of producing fused cells in the presence of ATP or its metabolite. A medicinal composition for regenerating or improving the function of a tissue or an organ, which suffers from dysfunction or hypofunction due to injury or denaturation, by using stem cells. This composition comprises ATP or its metabolite and a pharmaceutically acceptable carrier.Type: ApplicationFiled: January 13, 2011Publication date: May 12, 2011Applicants: Kowa Company, Ltd., Masafumi Kitakaze, Tetsuo Minamino, Akio HirataInventors: Masafumi Kitakaze, Tetsuo Minamino, Akio Hirata
-
Publication number: 20110097733Abstract: The invention concerns a process for the production of a hybridoma, and of a monoclonal antibody or fragments thereof able to recognize 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.Type: ApplicationFiled: October 26, 2010Publication date: April 28, 2011Inventors: Michel Anciaux, Fabienne Mathieu, Frédéric Lin, Martin Poncelet
-
Publication number: 20110053166Abstract: A stem cell expression cassette, comprising a nucleic acid comprising a pluripotent stem cell specific promoter, and a tag sequence, wherein the pluripotent stem cell specific promoter and tag sequences are operatively linked, is provided. Also provided are methods of identifying and methods of selecting a pluripotent cell, using the stem cell expression cassette.Type: ApplicationFiled: February 27, 2009Publication date: March 3, 2011Applicant: The Hospital for Sick ChildrenInventors: James Ellis, Akitsu Hotta
-
Publication number: 20110020934Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.Type: ApplicationFiled: April 6, 2010Publication date: January 27, 2011Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au
-
Publication number: 20110008344Abstract: This invention relates to a novel fusion partner cell line that ectopically expresses IL-6 and TERT termed B5-6T, and to methods for making the B5-6T fusion partner cell line. The B5-6T fusion partner cell line can be fused with B-lymphocytes to generate hybridomas that secrete human monoclonal antibodies.Type: ApplicationFiled: January 28, 2009Publication date: January 13, 2011Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Scott K. Dessain, Sharad P. Adekar
-
Methods Of Generating High-Production Of Antibodies From Hybridomas Created By In Vitro Immunization
Publication number: 20100311169Abstract: The invention provides methods for generating high titers of high-affinity antibodies from hybridoma cells produced by fusing myeloma cells with in vitro immunized donor cells. The hybridoma cells or mammalian expression cells with cloned antibody genes from the hybridomas producing the high-affinity antibodies may be mismatch repair defective due to defects of endogenous mismatch repair subunits of through expression of a dominant negative allele of a mismatch repair gene which allows the hybridoma cell to be hypermutable, may be rendered hypermutable by chemical means, or may be naturally mismatch repair deficient. High-affinity antibodies and high titer producer cells producing antibodies may be prepared by the methods of the invention.Type: ApplicationFiled: May 25, 2010Publication date: December 9, 2010Applicant: MORPHOTEK INC,Inventors: Luigi Grasso, Shaohong Liang, Nicholas C. Nicolaides, Philip M. Sass -
Publication number: 20100293627Abstract: An improved method of nuclear transfer employing long-term cultured somatic cells as the donor cells and enucleated oocytes as the recipient cells to produce dividing cybrids. Such cybrids are useful for developing viable animals clones when nurtured in a suitable host environment.Type: ApplicationFiled: January 18, 2010Publication date: November 18, 2010Applicants: UNIVERSITY OF CONNECTICUT, THE GOVERNOR OF KAGOSHIMA PREFECTUREInventors: Xiangzhong YANG, Chikara KUBOTA
-
Patent number: 7829293Abstract: The present invention concerns a member of the human chemokine CC protein family. In particular, isolated nucleic acid molecules are provided encoding the chemokine ?-15 protein. Chemokine ?-15 polypeptides are also provided. The invention further concerns diagnostic methods for detecting thymus disorders and therapeutic methods for modulating bone marrow cell proliferation and differentiation.Type: GrantFiled: October 2, 2006Date of Patent: November 9, 2010Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Brent L. Kreider, Craig A. Rosen
-
Publication number: 20100212032Abstract: Compositions and methods are provided for the efficient and reproducible generation of clone animals of all developmental stages. Also provided are methods of use of the same in reproductive and therapeutic cloning protocols.Type: ApplicationFiled: March 23, 2010Publication date: August 19, 2010Inventors: Michele Boiani, Kenneth John McLaughlin, Hans R. Scholer
-
Publication number: 20100205678Abstract: The invention pertains to the discovery that the presence of oocyte spindle associated factors in an enucleated oocyte improves oocyte quality and subsequently nuclear transfer. In particular, it was discovered that maintaining oocyte spindle factors in the oocyte after enucleation improves oocyte quality for use in nuclear transfer methodology.Type: ApplicationFiled: January 4, 2008Publication date: August 12, 2010Inventors: Eric W. Overstrom, Elena Ibáñez, Christine A. Lima
-
Publication number: 20100178702Abstract: The invention relates to membrane vesicles from non-pathogenic amoeba, in particular from the amoeba Dictyostelium discoideum, containing a molecule of therapeutic interest, to a method of preparing such vesicles and to the use of the vesicles as a vehicle for transferring the molecule therapeutic interest to an eukaryotic mammalian cell.Type: ApplicationFiled: March 22, 2010Publication date: July 15, 2010Applicant: UNIVERSITE PIERRE ET MARIE CURIE-PARIS VIInventors: Irène TATISCHEFF, Annette ALFSEN, Françoise LAVIALLE
-
Patent number: 7741072Abstract: A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region, which variant has a better binding affinity for human C1q than the parent polypeptide.Type: GrantFiled: October 12, 2007Date of Patent: June 22, 2010Assignee: Genentech, Inc.Inventors: Esohe Ekinaduese Idusogie, Leonard G. Presta, Michael George Mulkerrin
-
Publication number: 20100068813Abstract: Mammalian host cells for use in a cell-mediated tranfection process, which contain an RNAi molecule and an expression vector for a pro-apoptotic protein. The method includes inducing apoptotic cell (AC) death in mammalian cells that contain an RNAi molecule capable of downregulating a chosen target gene. Living cells expressing the target gene are then exposed to the ACs. The ACs are processed by the living cells, and the RNAi molecule in the ACs downregulates the expression of the target gene in living cells.Type: ApplicationFiled: September 28, 2007Publication date: March 18, 2010Applicant: LOMA LINDA UNIVERSITYInventors: Fengchun Li, Alan P. Escher
-
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
Patent number: 7666414Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.Type: GrantFiled: September 2, 2005Date of Patent: February 23, 2010Assignee: Cornell Research Foundation, Inc.Inventor: Neil Bander -
Publication number: 20100041103Abstract: A method of cell-fusion is provided, the method comprising fusing cells in a medium comprising a liquid composition having a liquid and nanostructures, each of the nanostructures comprising a core material of a nanometric size surrounded by an envelope of ordered fluid molecules, the core material and the envelope of ordered fluid molecules being in a steady physical state, thereby fusing cells. Compositions and articles of manufacture are also provided for generating monoclonal antibodies and culturing eukaryotic cells.Type: ApplicationFiled: January 3, 2008Publication date: February 18, 2010Inventor: Eran GABBAI
-
Publication number: 20100028946Abstract: Fusion partner cells that enable production of heterohybridomas even from cells of species other than mouse were produced by fusing myeloma cells derived from a first animal species with leukemia cells derived from a second animal species, which have an extra S phase in the cell cycle and have the property of diploidizing. Stable production of substances can be achieved by producing heterohybridomas through cell fusion between the fusion partner cells and substance-producing cells of an animal other than mouse.Type: ApplicationFiled: April 13, 2007Publication date: February 4, 2010Applicants: Medical & Biological Laboratories Co., Ltd.Inventors: Naomasa Yamamoto, Mizuho Kaneda
-
Patent number: 7638605Abstract: This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.Type: GrantFiled: May 3, 2004Date of Patent: December 29, 2009Assignee: ImClone, LLCInventor: Dale L. Ludwig
-
Patent number: 7612174Abstract: Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper ?-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypo ?-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like.Type: GrantFiled: March 12, 2007Date of Patent: November 3, 2009Assignee: Fuso Pharmaceutical Industries, Ltd.Inventor: Nobutaka Wakamiya
-
Patent number: 7612175Abstract: Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper ?-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypo ?-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like.Type: GrantFiled: March 12, 2007Date of Patent: November 3, 2009Assignee: Fuso Pharmaceutical Industries, Ltd.Inventor: Nobutaka Wakamiya
-
Publication number: 20090269371Abstract: Provided is a use of a recombinant chimaeric protein as an immunogen in a process for producing a monoclonal antibody, wherein the recombinant chimaeric protein is assembled into a virus-like particles, and includes a foreign protein or peptide or a fragment thereof.Type: ApplicationFiled: October 12, 2007Publication date: October 29, 2009Inventors: Aurelija Zvirbliene, Alma Gedvilaite, Rainer Ulrich, Kestutis Sasnauskas
-
Patent number: 7575896Abstract: The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods.Type: GrantFiled: November 8, 2007Date of Patent: August 18, 2009Assignee: Epitomics, Inc.Inventor: Guo-Liang Yu
-
Patent number: 7569675Abstract: A lagomorph derived monoclonal antibody for recognizing the progesterone receptor (PR) (clone SP2) with immunohistochemistry and methods for creating such an antibody are disclosed. No need of target retrieval in immunohistochemistry is their prominent advantage compared to currently available PR antibody. Furthermore, the very low background when the lagomorph derived monoclonal antibody is used in immunohistochemistry is also impressive. The immunohistochemistry comparative study with about fifty clinical specimens showed that the new PR antibody (clone SP2) antibody had favorable results when compared to mouse monoclonal antibody PR (clone 1A6), the best one in the current market. The PR antibody may prove of great value in the assessment of PR status in human breast cancer. Humanized versions of the PR antibody may provide therapeutic benefits.Type: GrantFiled: September 11, 2002Date of Patent: August 4, 2009Assignee: Spring Bioscience CorporationInventors: Haiying Xia, Zhida Huang
-
Patent number: 7557189Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.Type: GrantFiled: November 5, 2003Date of Patent: July 7, 2009Assignee: Immunogen Inc.Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
-
Publication number: 20090144841Abstract: The present invention relates to a polymorphic MRP-1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells.Type: ApplicationFiled: September 13, 2007Publication date: June 4, 2009Applicant: EPIDAUROS Biotechnologie AGInventors: Ulrich Brinkmann, Sven Hoffmeyer, Esther Mornhinweg
-
Patent number: 7514078Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.Type: GrantFiled: May 30, 2003Date of Patent: April 7, 2009Assignee: Cornell Research Foundation, Inc.Inventors: Neil H. Bander, Francis J. Carr, Anita Hamilton
-
Publication number: 20080267930Abstract: A method of producing a reprogrammed cell or reprogrammed cell nucleus, comprising exposing a differentiated cell, or the nucleus of a differentiated cell to a cell or cell extract thereof derived from an oocyte, egg, ovary or early embryo of a cold blooded vertebrate, wherein the cold blooded vertebrate has one or more of the following properties: (i) a primitive vertebrate body plan including laterally projecting ribs and/or spinal projections; (ii) germ cells which do not contain germ plasm; and/or (iii) the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses a highly conserved form of Oct-4 and/or nanog. There is also provided uses of the reprogrammed cells.Type: ApplicationFiled: July 21, 2006Publication date: October 30, 2008Applicant: The University of NottinghamInventors: Andrew Johnson, Keith Campbell, Ramiro Alberio
-
Patent number: 7442550Abstract: A method for detecting the expression of a polypeptide in cells and for detecting the interaction between a polypeptide and cells, ex vivo or in vitro, wherein the polypeptide is selected from the group consisting of: a peptide comprising the cyt domain of the envelope protein of the human endogenous retrovirus, HERV-W; a peptide comprising amino acids 448-538 of SEQ ID NO: 1; and a peptide comprising a sequence having, for any series of 20 amino acids, at least 80% identity with amino acids 448-538 of SEQ ID NO: 1. Detection is established by the fusogenic power of the polypeptide, which is demonstrated by syncytia formation.Type: GrantFiled: September 1, 2000Date of Patent: October 28, 2008Assignees: Biomerieux, Institut National de la Sante et de la Recherche MedicaleInventors: Francois Mallet, Francois-Loic Cosset, Jean-Luc Blond, Dimitri Lavillette, Olivier Bouton, Alessia Ruggieri
-
Patent number: 7432103Abstract: The present invention relates to cells that can be passaged in culture and can be used for, among other things, promoter assays and the production of heterologous proteins.Type: GrantFiled: February 1, 2008Date of Patent: October 7, 2008Assignee: AviGentics, Inc.Inventors: Jeffrey C. Rapp, Stephen H. Parker, Markley C. Leavitt, Dawn M. Eberhardt, Leandro Christmann, Alex J. Harvey
-
Publication number: 20080213387Abstract: The invention relates to cytotrophoblast stem cells derived from embryonic stem cells; their differentiation into endovascular cytotrophoblast cells; and uses thereof.Type: ApplicationFiled: October 16, 2007Publication date: September 4, 2008Applicant: AXORDIA LIMITEDInventors: Harry MOORE, Paul GERSKOWITCH, Rosliah HARUN
-
Patent number: 7407795Abstract: Two different strains of Cordyceps sinensis are placed at two different locations in a medium containing purified rattle snake venom and the two strains are allowed to grow until they meet in a boundary zone where a hybrid strain is formed due to exchange of genetic material. The hybrid strain is allowed to grow and is harvested and can be analyzed for the presence and quantity of desired medicinal substances. The amount of N6-(2-hydroxyethyl)-adenosine in a Cordyceps sinensis strain or product sample is a reliable indicator of the overall health benefiting qualities of the strain or sample. Strains of Cordyceps sinensis, are grown in a substrate at 20 to 22° C. at sea level atmospheric pressure for 28 to 30 days in diffuse light, and thereafter in an atmosphere containing approximately 50% of oxygen of the sea level atmosphere, at approximately 3° C.Type: GrantFiled: July 1, 2005Date of Patent: August 5, 2008Inventors: Phillip D. Cleaver, John C. Holliday, Megan Loomis Powers
-
Patent number: 7402409Abstract: The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods.Type: GrantFiled: January 23, 2003Date of Patent: July 22, 2008Assignee: Epitomics, Inc.Inventor: Guo-Liang Yu
-
Patent number: 7351582Abstract: The present invention relates to cells that can be passaged in culture and can be used for, among other things, promoter assays and the production of heterologous proteins.Type: GrantFiled: June 16, 2006Date of Patent: April 1, 2008Assignee: AviGenics, Inc.Inventors: Jeffrey C. Rapp, Stephen H. Parker, Markley C. Leavitt, Dawn M. Eberhardt, Leandro Christmann, Alex J. Harvey